(Q69054047)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

title

Adjuvant Bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Clinical results of a randomized trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

1 reference

transitional cell carcinoma

1 reference

1 reference

H Blomgren

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

I Näslund

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

P L Esposti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

L Johansen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

O Aaskoven

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

publication date

1 January 1987

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

29 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

29 September 2019

page(s)

41-46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3594491%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00199299

29 September 2019

exact match

0 references

cites work

Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial

1 reference

12 December 2020

Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors

1 reference

12 December 2020

Adjuvant immunotherapy in superficial bladder cancer

1 reference

12 December 2020

Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.

1 reference

12 December 2020

Decrease in saturation density of mammalian carcinoma cell culture during exposure to bestatin, a clinically applicable agent

1 reference

12 December 2020

Long term protection in bladder cancer following intralesional immunotherapy

1 reference

12 December 2020

Redifferentiation of cancer cells: bestatin, estradiol, and prostaglandin D2

1 reference

12 December 2020

Local BCG-immunotherapy in bladder cancer patients. Immunological follow-up studies

1 reference

12 December 2020

Effect of bestatin on mouse immune system and experimental murine tumors

1 reference

12 December 2020

Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma

1 reference

12 December 2020

Recent advances in bioactive microbial secondary metabolites

1 reference

12 December 2020

Active immunotherapy of cancer for minimal residual disease: new trends and new materials

1 reference

12 December 2020

Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase

1 reference

12 December 2020

Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study

1 reference

12 December 2020

Reductions of responder and stimulator capacities of peripheral lymphoid cells in the mixed lymphocyte culture following external radiotherapy

1 reference

12 December 2020

Prediction of survival and recurrence in bladder carcinoma

1 reference

12 December 2020

Bacillus Calmette-Guerin immunotherapy for bladder cancer

1 reference

12 December 2020

Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes

1 reference

12 December 2020

Restoration of impaired immune functions of aged animals by chronic bestatin treatment

1 reference

12 December 2020

The structure of bestatin

1 reference

12 December 2020

Restoration of E-rosette formation by bestatin in patients with bladder cancer

1 reference

12 December 2020

Radiation treatment of urinary bladder carcinoma

1 reference

12 December 2020

Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients

1 reference

12 December 2020

Cellular cytotoxicity in transitional cell carcinoma of the human urinary bladder - a summary

1 reference

12 December 2020

Enzyme inhibitors in relation to cancer therapy

1 reference

12 December 2020